Fresenius Medical Care AG & Co. KGaA
NYSE:FMSMedical - Care Facilities
-$0.18 today
- Market cap
- $11.26B
- Beta
- 0.81
- P/E (TTM)
- 11.9
- EPS (TTM)
- $3.43
- Dividend yield
- 3.65%
Volume 1.92M
Average 0.72M
FMS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Fresenius Medical Care AG & Co. KGaANYSE: FMS
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of €828.97M rose 0.8% year over year, behind the +8.2% change in trailing-twelve-month EBITDA. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.
Context
- EBITDA amounted to 17.3% of revenue in FY2025, up 0.7 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of €3.27B (-3.8%) for the fiscal year ending Dec 2026, a slowdown from the +6.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- €828.97M+8.5% QoQ
- Last fiscal yearDec 2025
- €3.4B+6.0% YoY
- LTMJun 2026
- €3.43B+8.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.8% | -1.6% | -2.4 pp |
| 1 year | +6.0% | -3.8% | -9.8 pp |
| 3-year CAGR | -0.2% | -1.4% | -1.2 pp |
| 5-year CAGR | +2.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- 3.4B EUR
- Year-over-year change
- +6.0%
- 4-year CAGR
- -1.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.4B | +6.0% |
| FY2024 | 2024-12-31 | 3.21B | -0.1% |
| FY2023 | 2023-12-31 | 3.21B | -6.1% |
| FY2022 | 2022-12-31 | 3.42B | -3.7% |
| FY2021 | 2021-12-31 | 3.55B | — |
EBITDA vs competitors
How FMS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.2% is the highest of 4, against a peer median of -220.1%.
- EBITDA amounts to 17.6% of revenue for FMS, versus a peer median of 16.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €3.43B EUR | +8.2% | -0.2% | 17.6% | |
| LTM Jun 2026 | $2.76B USD | +2.0% | +8.7% | 19.7% | |
| LTM Mar 2026 | -$5.76M USD | -220.1% | +92.3% | 2.5% | |
| LTM Sep 2026 | -$106.58M USD | -372.0% | — | 16.4% | |
| Peer median (excluding FMS) | — | -220.1% | +50.5% | 16.4% | |
Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B |
| Cost of Revenue | 12.85B | 14.5B | 14.53B | 14.58B | 14.6B |
| Gross Profit | 4.77B | 4.89B | 4.93B | 4.76B | 5.03B |
| Gross Margin | 27.1% | 25.2% | 25.3% | 24.6% | 25.6% |
| Research & Development | 220.78M | 228.62M | 231.97M | 183.49M | 157.98M |
| Selling, General & Admin | 2.77B | 3.17B | 3.2B | 3.14B | 3.03B |
| Operating Expenses | 2.92B | 3.38B | 3.56B | 3.29B | 3.2B |
| Depreciation & Amortization | 1.62B | 1.84B | 1.75B | 1.74B | 1.5B |
| EBITDA | 3.55B | 3.42B | 3.21B | 3.21B | 3.4B |
| EBITDA Margin | 20.1% | 17.6% | 16.5% | 16.6% | 17.3% |
| Operating Income | 1.85B | 1.51B | 1.37B | 1.47B | 1.83B |
| Operating Margin | 10.5% | 7.8% | 7.0% | 7.6% | 9.3% |
| Interest Income | 73.17M | 67.66M | 88.22M | 71.58M | 69.61M |
| Interest Expense | 353.6M | 360.14M | 424.64M | 407.04M | 384.41M |
| Other Income / Expenses | (280.43M) | (292.48M) | (336.42M) | (410.45M) | (314.59M) |
| Income Before Tax | 1.57B | 1.22B | 1.03B | 1.06B | 1.51B |
| Pre-Tax Margin | 8.9% | 6.3% | 5.3% | 5.5% | 7.7% |
| Income Tax Expense | 352.83M | 324.95M | 300.56M | 316.06M | 320.97M |
| Net Income | 969.31M | 673.41M | 499M | 537.91M | 978.37M |
| Net Margin | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% |
| EPS (Basic) | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| EPS (Diluted) | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| Weighted Avg Shares | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
| Weighted Avg Shares (Diluted) | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
Intrinsic Alpha fair value
Locked
Current Price
$20.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.